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Background: The expression pattern and function of miRNAs in the rat model of temporal lobe epilepsy have not
been well defined. Profiling miRNA expression in the rat model of temporal lobe epilepsy and investigating the
function of specific miRNAs in epilepsy offers the prospect of a deeper understanding of the mechanisms of
epilepsy.
Methods: The lithium-pilocarpine-induced status epilepticus model and the temporal lobe epilepsy model were
established in Sprague–Dawley rats. Samples were analysed to detect deregulated miRNAs in the hippocampal
temporal lobe, and several of these deregulated miRNAs were confirmed by qPCR. The expression of the
pro-apoptotic miR-34a was detected at 1 day, 7 days and 2 weeks post-status epilepticus and at 2 months after
temporal lobe epilepsy. The antagomir of miR-34a was then utilised. The expression of miR-34a after targeting and
the expression change of activated caspase-3 protein were examined. The effects of altering the expression of
miR-34a and activated caspase-3 protein on neuronal survival and neuronal death or apoptosis post-status
epilepticus were assessed.
Results: The miRNA microarray detected 9 up-regulated miRNAs (miR-146a, -211, -203, -210, -152, -31, -23a, -34a,
-27a) and 15 down-regulated miRNAs (miR-138*, -301a, -136, -153, -19a, -135b, -325-5p, -380, -190, -542-3p, -33, -144,
-542-5p, -543, -296*). Some of the deregulated miRNAs (miR-146a, miR-210, miR-27a, miR-135b and miR-33) were
confirmed using qPCR. Furthermore, an increase in expression of the pro-apoptotic miR-34a was demonstrated in
the post-status epilepticus rat hippocampus. miR-34a was significantly up-regulated at 1 day, 7 days and 2 weeks
post-status epilepticus and at 2 months after temporal lobe epilepsy. Experiments with the miR-34a antagomir
revealed that targeting miR-34a led to an inhibition of activated caspase-3 protein expression, which may
contribute to increased neuronal survival and reduced neuronal death or apoptosis.
(Continued on next page)* Correspondence: xiaobo62_xy@126.com
†Equal contributors
1Department of Neurology, Xiangya Hospital, Central South University,
Changsha, Hunan 410008, P. R. China
Full list of author information is available at the end of the article
© 2012 Hu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hu et al. BMC Neuroscience 2012, 13:115 Page 2 of 14
http://www.biomedcentral.com/1471-2202/13/115(Continued from previous page)
Conclusions: Our study showed the expression profile of miRNAs in the hippocampus in a rat model of temporal
lobe epilepsy and an increase in the expression of the pro-apoptotic miR-34a in post-status epilepticus rats. The
results show that miR-34a is up-regulated during seizure-induced neuronal death or apoptosis, and targeting
miR-34a is neuroprotective and is associated with an inhibition of an increase in activated caspase-3 protein.
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MicroRNAs (miRNAs) belong to a family of non-coding
small RNAs and are emerging as important post-
transcriptional regulators that either inhibit mRNA
translation or direct target mRNA degradation [1]. They
are critical for normal neuronal development and may
be involved in many neurological diseases whose
mechanisms remain to be explored. For example, miR-
NAs have important roles in gene regulatory networks
involved in both brain development and adult neural
plasticity [2]. miR-124a and miR-9 are able to regulate
ES cell differentiation toward neuronal or glial lineages
[3], and brain-specific miR-9 is critical in modulating the
cellular behaviour of stem cell-derived neural progenitor
cells (NPCs) [4]. Recent work by Agostini et al. found
that pro-apoptotic miR-34a regulates neurite outgrowth,
spinal morphology and function [5], and this work high-
lights the importance of miR-34a in neuronal differenti-
ation and synaptogenesis. The studies described above
are only a few examples of the involvement of miRNAs
in the nervous system.
A number of studies have investigated the role of miR-
NAs in neurological diseases such as epilepsy. Using the
pilocarpine mouse model of epilepsy, Nudelman et al.
reported that neuronal activity rapidly induces transcrip-
tion of the CREB-regulated miR-132 in vivo [6]. This
was the first study to demonstrate a change in a miRNA
after seizures. Sano and Henshall reported that miR-34a
is up-regulated during seizure-induced neuronal death
[7] and concluded that prolonged seizures cause up-
regulation of miR-34a in a subfield-specific, temporally
restricted manner. However, they suggested that miR-34a
is most likely not important for seizure-induced neur-
onal death in the mouse model. Recently, Kan et al.
published a study of miRNA profiles in human temporal
lobe epilepsy (TLE) [8] and extended the current con-
cepts of human mesial TLE pathogenesis to the level of
miRNA-mediated gene regulation. Before Kan’s work in
human TLE, Aronica et al. had also published a paper
focused on a single inflammation-associated miR-146a
in TLE patients [9]. More recently, the work of Henshall
et al. showed that miR-134a silencing produces neuro-
protective and prolonged seizure-suppressive effects
[10]. One of their previous studies suggested that target-
ing miR-132 reduces seizure-induced neuronal deathand protects the hippocampus [11]. Both studies offered
a new therapeutic target for the treatment of epilepsy.
Epigenetic research of miRNAs associated with epi-
lepsy is an interesting field and more findings are emer-
ging. Most studies have focused on the function of
brain-specific miRNAs following status epilepticus in the
mouse model or on samples from TLE patients. The ex-
pression and functional changes of inflammation-,
development- and neuronal death-associated miRNAs in
epilepsy have been identified. However, studies addres-
sing the roles of pro-apoptotic miRNAs in the mechan-
ism of epilepsy using different models are limited. The
study of miR-34a in the mouse model of epilepsy has
delineated a restricted role for this pro-apoptotic
miRNA. Whether miR-34a mediates seizure-induced
neuronal death and how it is involved in that process in
the widely used status epilepticus (SE) rat model remains
to be explored.
The lithium-pilocarpine-induced SE rat model is a reli-
able model to study status epilepticus and temporal lobe
epilepsy [12,13]. Using this model, we have detected an
aberrant miRNA expression pattern in the rat hippo-
campus and confirmed the presence of significantly
deregulated miRNAs. Because miR-34a was up-regulated
in this work and in a previous study [14], we hypothe-
sized that miR-34a is up-regulated in the rat hippocampus
after status epilepticus and contributes to seizure-induced
neuronal death. Our results showed that miR-34a is up-
regulated in rats after status epilepticus and targeting
miR-34a in vivo could alleviate seizure-induced neuronal
death or apoptosis and increase the number of surviving
neurones in the hippocampus. This research indicates the
neuroprotective effects of targeting miR-34a in seizure-
induced neurone cell death or apoptosis in post-status epi-
lepticus rats.Methods
Ethical statement
Animal care and sacrifice were conducted according to
methods approved by the Animal Care and Use Com-
mittee, Xiangya Medical College, Central South Univer-
sity. All experiments were performed in accordance with
the National Institute of Health Guide for the Care and
Use of Laboratory Animals.
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Male Sprague–Dawley (SD) rats (6–8 weeks of age,
weighing 230–270 g, from the Animal Unit, Central
South University, P. R. China) were used. All animals
were housed in a room kept on an alternating 12 hours
light–dark cycle with a controlled temperature (18°C -
25°C) and humidity (50% - 60%). Food and water were
available ad libitum.
Study design, sample size and animal allocation
The study design and animal allocation are outlined in
Additional file 1. Because there was a loss of animals
post-SE and some animals did not exhibit spontaneous
seizures, the number of animals used in the study was
somewhat larger. The study design, animal allocation
and number of animals used for statistical analyses are
listed in the notes of Additional file 1, and the selection
of animals was random whenever it was possible.
Regarding the sample size, there were 152 SD rats used
in the entire study, and 102 total rats were included in
the statistical analyses.
Experimental procedures for the SE and TLE model
Lithium chloride (125 mg/kg, i.p., Sigma, USA) was
injected 18–20 hours prior to the administration of pilo-
carpine (20 mg/kg, i.p., Sigma). The severity of convul-
sions was evaluated by Racine’s scale, and only those
animals that were classified with a score of 4–5 were
included in this study. SE was defined as the onset of
continuous generalised (Racine’s scale score 4–5) seizure
activity lasting no less than 40 min. Intraperitoneal pilo-
carpine administration (10 mg/kg) was repeated every
30 min if there were no seizures or seizure activity was
classified lower than a score of 4 on Racine’s scale. The
maximum dose for pilocarpine injection was 60 mg/kg.
All SE rats received chloral hydrate (10%, 3 ml/kg, i.p.)
to terminate epileptic attacks. The control rats received
an injection of an equal amount of normal saline instead
of pilocarpine. All the rats were housed in the same en-
vironment and continuous observation of animal behav-
iour was performed from the successful establishment of
the SE model to the time of the animal’s death. The tem-
poral lobe epilepsy rats (2 months post-SE) were identi-
fied by a frequent attack of seizures (at least two
spontaneous seizures that scored 4–5 on Racine’s scale),
either by direct observation or by videotape recordings.
Some animals exhibiting seizures were confirmed using
electroencephalogram (EEG) recordings that displayed
high frequency, high amplitude, poly-spike paroxysmal
discharges. The animals were killed within 5 hours of oc-
currence of the last spontaneous seizure. Some animals
were anesthetised using chloral hydrate (10%, 5 ml/kg, ip.)
and decapitated, and hippocampi were removed
quickly from the brain and frozen in liquid nitrogen.Other animals were anesthetised and perfused with
saline followed by 4% paraformaldehyde.
miRNA microarray analysis
Total RNA for microarray analysis was extracted and
purified using the mirVana™ miRNA Isolation Kit (Cat#
AM1560, Ambion, Austin, TX, US) following the manu-
facturer’s instructions and checked for a RIN number to
inspect RNA integrity using an Agilent Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA, US).
miRNA molecules in the total RNA were labelled by a
miRNA Complete Labeling and Hyb Kit (Cat# 5190–
0456, Agilent Technologies, Santa Clara, CA, US) fol-
lowing the manufacturer’s instructions.
Each slide was hybridised with 100 ng of Cy3-labeled
RNA using the miRNA Complete Labeling and Hyb Kit
(Cat# 5190–0456, Agilent Technologies, Santa Clara,
CA, US) in hybridisation Oven (Cat# G2545A, Agilent
Technologies, Santa Clara, CA, US) at 55°C and 20 rpm
for 20 hours according to the manufacturer’s instruc-
tions. After hybridisation, the slides were washed in
staining dishes (Cat# 121, Thermo Shandon, Waltham,
MA, US) with the Gene Expression Wash Buffer Kit
(Cat# 5188–5327, Agilent Technologies, Santa Clara,
CA, US).
Slides were scanned using the Agilent Microarray
Scanner (Cat# G2565BA, Agilent Technologies, Santa
Clara, CA, US) and the Feature Extraction software 10.7
(Agilent Technologies, Santa Clara, CA, US) with the
default settings. Subsequently, the microarray image in-
formation was converted into spot intensity values using
the Scanner Control Software Rev. 7.0 (Agilent Tech-
nologies, Santa Clara, CA, US). The signal after back-
ground subtraction was later exported directly into the
Gene Spring GX11.0 software (Agilent Technologies,
Santa Clara, CA, US) for quantile normalisation. The
quantile algorithm is a method of normalisation that
equalises the distribution of expression values of all the
samples in an experiment. The mean normalised signal
from biological replicates was then used for comparative
expression analysis. The unpaired t-test with the
Benjamini-Hochberg correction was used to identify dif-
ferentially expressed miRNAs between the control and
epilepsy samples. The significantly deregulated miRNAs
were defined as miRNAs that have p-values less than
0.05 and with an expression fold-change greater than
1.5, whether they were up-regulated or down-regulated
when compared with controls. Normalised data were
hierarchically clustered by gene and used to plot the heat
maps.
Quantitative real-time PCR
Total RNA was isolated using the Trizol reagent (Invi-
trogen, USA). Each reaction mixture of RT contained
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with RNase-free H2O to 11 μL (volume A) and 5 μL RT
buffer 5X, 0.5 μL 2.5 mM dNTPs, 1 μL RNase Inhibitor
(40 U/μL), 0.5 μL Reverse Transcriptase (200 U/μL)
(Fermentas) and RNase-free H2O to a total volume of 25
μL. The 11 μL volume A was mixed and centrifuged at
4°C, incubated for 10 min at 70°C and placed in an ice
bath for 2 min. The 25 μL volume reactions were then
incubated for 60 min at 42°C and for 10 min at 70°C.
qPCR reaction was performed using the Platinum
SYBR Green qPCR Super Mix UDG (Invitrogen, USA)
and ABI Mx3000P QPCR System (Stratagene). qPCR
was performed in triplicates. The 20 μL qPCR reaction
contained the following: 9 μL SYBR Green Mix, 2 μL
miRNA RT Product, 2 μL Bulge-LoopTM miRNA For-
ward Primer (5 μM) and 2 μL Bulge-LoopTM miRNA
Reverse Primer (5 μM) (RiboBio Co., Ltd, China) and
RNase-free H2O to a final volume of 20 μL. The qPCR
reactions were incubated at 95°C for 20 s, followed by
40 cycles of 95°C for 10 s, 60°C for 20 s and 70°C for
10 s and finally 95°C for 10 s, 60°C for 20 s and 95°C for
10 s.
The relative expression level for each miRNA was cal-
culated by the comparative CT method. The expression
of the U6 small nucleolar RNA gene was used as an in-
ternal control.
Bioinformatics analysis
All significant differentially expressed miRNAs were ana-
lysed by bioinformatics algorithms. Potential targets of
these miRNAs were predicted using the miRNA target
prediction databases including TargetScan and miRanda.
Functional classification was performed by Gene Ontol-
ogy (GO) to determine the biological significance of
these targets, and an accompanying p-value calculated
by the Fisher’s Exact Test indicated which functions
were over-represented in the targets. Moreover, using
the KEGG pathway database, pathway analysis was per-
formed to identify the enriched pathways of targets, and
the p-value was calculated for each pathway using a
hyper-geometric distribution for identification of the sig-
nificance of pathways.
miR-34a antagomir experiments
To study the potential function of miR-34a in post-SE
rat hippocampal neuronal apoptosis, a miRNA antago-
mir strategy was adopted. We antagonised the expres-
sion of miR-34a in post-SE rat hippocampus by using an
antagomir that specifically targets miR-34a. A miR-34a
antagomir or an antagomir-control (miR-RiboTM; Ribo-
Bio Co., Ltd., China) was dissolved in an artificial CSF
(119 mmol/L NaCl, 3.1 mmol/L KCl, 1.2 mmol/L CaCl2,
1 mmol/L MgSO4, 0.5 mmol/L KH2PO4, 25 mmol/L
NaHCO3, 5 mmol/L D-glucose, 2.2 mmol/L urea, pH7.4) [15] at a concentration of 20 nmol/mL (1 nmol/50
μL for each rat) and infused at a very slow rate (25 μL of
CSF was withdrawn for an hour and 50 μL of antagomir
was infused for 2 hours) by micro- syringe into the lat-
eral ventricle (Bregma: 0.8 mm posterior, -4.8 mm
dorsoventral, -1.5 mm lateral; on the basis of the rat
brain atlas of Paxinos and Watson [13]) of post-SE rats.
The process began at 1 hour and ended at 4 hours after
SE onset. To look for expression changes of miR-34a
and its potential downstream molecules in post-SE rats
that had received infusions of miR-34a antagomir and
antagomir-control, rats were anesthetised using chloral
hydrate (10%, 5 mL/kg, ip.) at 7 days post-SE before
their hippocampal tissue was removed for detection of
miR-34a expression and detection of its potential down-
stream molecules including activated caspase-3 protein.
Western-blot analysis
The cytoplasmic extracts were separated by 12% SDS-
PAGE and transferred onto a PVDF membrane using
the Bio-Rad system (Bio-Rad, USA) before blocking with
TBST containing 5% nonfat-milk for 2 hours at room
temperature with gentle shaking. Three washing steps of
10 min each were performed after blocking and incuba-
tion with the antibodies. The primary antibody was a
rabbit anti-rat activated caspase-3 polyclonal antibody
(Abcam, ab2302; 1:600); β-actin expression was used as
an internal control. The membrane was incubated over-
night at 4°C with the primary antibody and incubated
with a goat anti-rabbit IgG/HRP antibody (SCBT,
sc-2030; 1:40,000) at room temperature for 1 h. The pro-
tein/antibody complexes were detected using chemilu-
minescence reagents (ECL) (KPL, USA). Integrated
optical density (IOD) values of activated caspase-3 pro-
tein and β-actin were measured. The relative expression
amount of activated caspase-3 protein was determined
by the ratio of activated caspase-3 protein/β-actin.
Immunohistochemistry
The paraffin-embedded sections were deparaffinised and
rehydrated, followed by treatment with 1% hydrogen per-
oxide to eliminate endogenous peroxidase activity. After
treatment with goat serum reagent at room temperature
for 20 min, the sections were exposed to primary antibody
for 2 h at room temperature and overnight at 4°C. The
primary antibody was a rabbit anti-rat caspase-3 poly-
clonal antibody (Boster Co., China; 1:200). The sections
were incubated with secondary antibody, a biotinylated
goat anti-rabbit antibody (Boster Co., China; 1:200) at
room temperature for 20 min, followed by incubation with
a streptavidin-biotin peroxidase complex solution (Boster
Co., China) at room temperature for 90 min. Subse-
quently, the sections were stained using diaminobenzidine,
restained with hematoxylin, dehydrated and mounted. All
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Analysis system for imaging and analysis.
Nissl staining and TUNEL assay
Nissl staining was performed to detect the surviving
neurones. The sections were stained with 0.5% Cresyl
violet (w/v) for 10 minutes before they were dehydrated
and mounted with permount. The surviving neurones
were only counted if they possessed intact neuronal
morphology. The TUNEL assay, which detects DNA
fragmentation resulting from apoptotic signalling cas-
cades, was performed to label apoptotic neurones. It
may also label cells that have suffered severe DNA dam-
age. Therefore, the TUNEL assay is helpful in identifying
seizure-induced neuronal death in our experiments. The
procedures were performed according to the manufac-
turer’s instructions (Roche Co., Germany). TUNEL-
positive cells were defined as those demonstrating
blue-purple nucleic staining. The CA1 and CA3 regions
of each section were captured by microscope (Olympus,
Japan). Under 40 ×magnification, 6 visual fields were
randomly selected for each section, and the surviving
neurones and the total number of cells were counted.
The survival rate was calculated as follows: number of
surviving neurones/total number of cells × 100%. Add-
itionally, 6 visual fields were randomly selected to count
the number of dead neuronal cells and the total number
of cells. The death rate was determined as follows: num-
ber of dead neuronal cells/total number of cells × 100%.
For Nissl-staining or TUNEL-assay, three sections were
examined for each rat before the means were obtained
for statistical analysis.
Statistical methods
Statistical analysis was performed using the SPSS 13.0
software and all data were expressed as the mean± stand-
ard deviation. Differences between multiple groups were
statistically assessed by one-way ANOVA analysis,
whereas differences between two groups were evaluated
by the independent-samples t-test. For statistical analysis,
p< 0.05 was considered to be statistically significant.
Results
Animal number analysed
The number of animals in each group included in each
analysis is reported in Additional file 1. Absolute num-
bers were used in the report. The animals and data not
included in the analysis, as well as their reasons, are also
clearly mentioned in the notes of Additional file 1.
miRNA expression profile of the hippocampus in a rat
model of TLE
The Agilent Rat miRNA microarray used in this study
covered over 350 rat miRNAs detected so far, and thesequence information is based on the Sanger miR-Base
version 12.0. The miRNA microarray scanned images
and the normalised primary microarray data are shown
in Additional files 2 and 3, respectively. The cluster and
heatmap of all detected rat miRNAs in this study are
plotted and shown in Figure 1. The miRNA microarray
differential analysis resulted in 24 significantly deregu-
lated miRNAs as shown in Table 1, and the heatmap of
these 24 aberrantly expressed miRNAs is plotted and
shown in Figure 2. Among the 24 significantly deregu-
lated miRNAs, 9 miRNAs (miR-146a, -211, -203, -210,
-152, -31, -23a, -34a, -27a) were up-regulated and 15
miRNAs (miR-138*, -301a, -136, -153, -19a, -135b, -325-
5p, -380, -190, -33, -542-3p, -144, -542-5p, -543, -296*)
were down-regulated (differentially expressed miRNAs
were defined by a fold-change >1.5, either up-regulated
or down-regulated; *p <0.05).
miRNA confirmation using qPCR
To validate the altered expression of miRNAs as
detected by miRNA microarray, miR-146a, miR-210,
miR-27a, miR-135b and miR-33 were selected for con-
firmation by quantitative real-time PCR. The results
were consistent with that of the microarray analysis.
As seen in Figure 3, the expression levels of miR-146a,
miR-210 and miR-27a were up-regulated, while the ex-
pression levels of miR-135b and miR-33 were down-
regulated (*p < 0.05).
Bioinformatics analysis
There were 1315 and 8810 target genes predicted by
microRNA target prediction databases TargetScan and
miRanda. The GO terms significantly over-represented
in deregulated miRNA targets are listed in Figure 4,
where the percent and enrichment test p values for each
GO term are indicated. Some of the top KEGG pathways
important in the molecular mechanism of epilepsy are
significantly over-represented among the deregulated
miRNA targets and are listed in Additional file 4. The
signalling pathways enriched in temporal lobe epilepsy
are consistent with previous studies of the molecular
portrait of basic epilepsy mechanisms using whole tran-
scriptome analysis of the hippocampus [16].
miR-34a expression post-SE
Expression of the pro-apoptotic miR-34a in the rat
hippocampus was examined. The time points chosen
for miR-34a detection were 1 day, 7 days, 2 weeks
post-SE and 2 months (TLE). The expression pattern
of miR-34a is shown in Figure 5. Pro- apoptotic
miR-34a was significantly increased in post-SE rat
hippocampus at all four time points chosen (*p <0.05).
Its over-expression was notably higher at 1 day,
7 days and 2 weeks post-SE before it went down to a
Figure 1 The heatmap of all rat hippocampal TLE miRNAs.
Rows represent individual genes, and columns represent individual
samples. The high (red), average (black) and low (green) expression
levels are depicted by the colourgram (n = 6 for TLE rats and n= 6
for control).
Table 1 The 24 significantly deregulated miRNAs in the
TLE rat hippocampus
MicroRNA Fold change Regulation p value
rno-miR-146a 2.6958885 up 1.258E-02
rno-miR-211 2.610144 up 1.376E-02
rno-miR-203 2.109093 up 2.367E-02
rno-miR-210 1.8106444 up 1.999E-02
rno-miR-152 1.7704262 up 8.17E-04
rno-miR-31 1.6925983 up 3.811E-03
rno-miR-23a 1.5156718 up 7.727E-03
rno-miR-34a 1.4842122 up 2.398E-02
rno-miR-27a 1.4451101 up 1.133E-02
rno-miR-138* 1.5289445 down 3.512E-02
rno-miR-301a 1.5327321 down 7.925E-03
rno-miR-136 1.5330569 down 4.166E-03
rno-miR-153 1.5534221 down 1.826E-02
rno-miR-19a 1.6450298 down 1.832E-02
rno-miR-135b 1.657749 down 2.853E-02
rno-miR-325-5p 1.8619193 down 4.587E-02
rno-miR-380 1.8745395 down 1.176E-02
rno-miR-190 1.8834999 down 1.528E-02
rno-miR-542-3p 1.8835889 down 7.955E-03
rno-miR-33 1.9224428 down 3.279E-03
rno-miR-144 1.9507241 down 4.969E-02
rno-miR-542-5p 2.2845843 down 5.943E-03
rno-miR-543 3.0247948 down 1.067E-03
rno-miR-296* 3.0831256 down 2.85E-06
Notes: The Agilent rat miRNA microarray identified 24 significantly
deregulated miRNAs (fold change >1.5, expression either upregulated or
down-regulated; *p <0.05) in the hippocampus of the TLE rat when compared
with the control (n = 6 for each group).
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though it was still markedly higher than control.miR-34a antagomir outcomes
miR-34a antagomir treatment significantly reduced the
expression of miR-34a in the rat hippocampus at 7 days
post-SE (*p <0.05), when compared with the miR-34a
antagomir-control-treated group (Figure 6A). Further-
more, the miR-34a antagomir specifically targeting
miR-34a did not exert any antagonising effects on other
miRNAs in the rat hippocampus at 7 days post-SE (data
not shown). The use of miRNA antagomirs is a successful
strategy for studies of miRNA function, both in vivo and
in vitro, because antagomirs effectively and specifically in-
hibit endogenous miRNAs by causing their degradation
with effects that persist at least one week or longer
(Instructions for miR-RiboTM Antagomir and Antagomir-
control; RiboBio Co., Ltd., China).
Figure 2 The heatmap of differentially expressed hippocampal
miRNAs in the TLE rat. The 24 significantly deregulated miRNAs
have been rearranged in this heatmap, where 9 up-regulated and 15
down-regulated miRNAs are clearly displayed (n = 6 for TLE rats and
n= 6 for control).
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The Western blot results demonstrated an up-regulation
of activated caspase-3 protein expression at 7 days post-
SE in the rat hippocampus, when compared with the
control (*p <0.05) (Figure 6B). Moreover, the expression
level of activated caspase-3 protein at 7 days post-SE inFigure 3 The quantitative real-time PCR validation for some expressio
(miR-146a, miR-210, miR-27a, miR-135b and miR-33) in the TLE rat hippocam
qPCR (Data are presented as the mean± SEM, *p <0.05; n = 6/TLE rats, n = 6the rat hippocampus decreased after miR-34a antagomir
treatment, when compared with the miR-34a antagomir-
control-treated group (*p <0.05) (Figure 6B). Immuno-
histochemistry confirmed the western blot results shown
in Figure 7, where the activated caspase-3 protein was
significantly over-expressed in the post-SE rat hippocam-
pal CA1 region and CA3 regions (Figure 7F and
Figure 7J) when compared with the control (Figure 7E
and Figure 7I). Moreover, activated caspase-3 protein ex-
pression was significantly down-regulated in the post-SE
rat hippocampal CA1 and CA3 regions after miR-34a
antagomir treatment (Figure 7G and Figure 7K) when
compared with the antagomir-control-treated group
(Figure.7H and Figure 7L).
Alterations in neuronal survival and neuronal death
Nissl-staining was performed to detect surviving neu-
rones, and the TUNEL-assay was used to label apoptotic
neurones by detecting the DNA fragmentation that
results from apoptotic signalling cascades. It may also
label cells that have suffered severe DNA damage.
TUNEL is therefore helpful for identifying seizure-
induced neuronal death in our experiments.
In the post-SE rat hippocampus, neuronal survival
decreased, whereas neuronal death increased (at 7 days
post-SE) (Table 2, Figure 8 and Figure 9). As seen, neur-
onal survival was reduced in the post-SE rat hippocam-
pal CA1 and CA3 regions (Figure 9F and Figure 9J;
Figure 9E and Figure 9I as control), and neuronal death
increased in the CA1 and CA3 regions (Figure 8F and
Figure 8J; Figure 8E and Figure 8I as controls).
miR-34a antagomir treatment had an inhibitory effect
on activated caspase-3 protein expression and led to an
increase in neuronal survival as well as a decrease in
seizure-induced neuronal death at 7 days post-SE in the
rat hippocampus (Table 2, Figure 8 and Figure 9). The
number of surviving neurones was markedly increased
in the CA1 and CA3 regions (Figure 9G and Figure 9K;
Figure 9H and Figure 9L as controls) when compared
with the antagomir-control-treated group. Additionally,n-altered miRNAs. The five differentially expressed miRNAs
pus as detected by the Rat miRNA microarray were confirmed using
/control). White bars: control; Black bars: experimental.
Figure 4 GO terms significantly over-represented among the deregulated miRNA targets are shown. The percent and enrichment test
p value for each GO term are indicated in this figure.
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Figure 5 The expression pattern of miR-34a is shown. The study time points were 1 day, 1 week, 2 weeks (post-SE) and 2 months (TLE). The
pro-apoptotic miR-34a displayed increased expression at all four time points chosen (Data are presented as the mean± SEM, *p <0.05; n = 6 for
each group), when compared with control.
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http://www.biomedcentral.com/1471-2202/13/115there was a significant decrease in neuronal cell death
after miR-34a antagomir treatment in the post-SE rat
hippocampal CA1 and CA3 regions (Figure 8G and
Figure 8K; Figure 8H and Figure 8L as controls) when
compared with the control.
Discussion
Because a number of previous studies have investigated
the role of miRNAs in epilepsy [6-11,14,17], it is important
to provide a discussion of our own data in light of previ-
ously published profiles and results. Different models may
yield different study outcomes, and comparisons of results
between different or even the same models are necessary.
Similar to our study, Song et al. used the classical statusFigure 6 The results of the miR-34a antagomir experiment. Inhibition
the rat hippocampus is shown in. A. The miR-34a antagomir significantly in
when compared with the antagomir-control (Data are presented as the me
caspase-3 protein in the post-SE rat hippocampus both before and after m
blot analysis is shown in B. Western blot detected an up-regulation in the
hippocampus, when compared with control (*p <0.05, n = 6 for each group
the rat hippocampus, however, decreased in the miR-34a antagomir-treate
(**p< 0.05, n = 6 for each group).epilepticus rat model and reported differential expression
of miRNAs in the hippocampus in a rat model of TLE
[17]. Yet, the number of samples used for miRNA micro-
array analysis (TLE rats = 3, control rat = 1) in their study
did not strictly conform to the limits needed for statistical
analysis. Furthermore, the standards to screen differen-
tially expressed miRNAs in their study (fold-change: three
ratios >1 plus at least two ratios >1.5 for up-regulated
miRNAs; three ratios <1 plus at least two <0.67 for down-
regulated miRNAs) did not meet the stringent conditions
of the method for analysing miRNA microarray raw data;
the overall inclusion of all data, where miRNA signal in-
tensities and all microarray values are integrated for statis-
tics, appears to be preferable. Therefore, we investigatedof miR-34a expression by the miR-34a antagomir at 7 days post-SE in
hibited the expression of miR-34a in the post-SE rat hippocampus
an± SEM, *p < 0.05; n = 6 for each group). The expression of activated
iR-34a antagomir/antagomir-control treatments as detected by western
expression of activated caspase-3 protein at 7 days post-SE in the rat
). The expression of activated caspase-3 protein at 7 days post-SE in
d group, when compared with the antagomir-control-treated group
Figure 7 Activated caspase-3 protein in the post-SE rat hippocampus. Overview: A-D; CA1 region: E-H; CA3 region: I-L. Scale bars: 300 μm
(A-D); 30 μm (E-L).
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http://www.biomedcentral.com/1471-2202/13/115the miRNA expression profile of TLE in the rat hippocam-
pus using a more rigorous design of animal numbers (TLE
rats = 6, control = 6) and method of analysing microarray
raw data. The results from our study were different to
some extent from Song’s report. There were some com-
mon differentially expressed miRNAs in the two studies;
e.g., both detected an up-regulation of the inflammation-
associated miR-146a and the apoptotic miR-23a. However,
many differentially expressed miRNAs detected varied be-
tween the two studies. For example, the pro-apoptotic
miR-34a was detected in our study as a significantly
deregulated miRNA, and further investigation of the ex-
pression and function of miR-34a in the mechanism of
epilepsy was performed.
To extend the animal studies to human research, Kan
et al. recently detected miRNA profiles in human TLE
and reported marked aberrant expression of miRNAs inTable 2 Neuronal death (apoptosis) and neuronal survival at
Neurones Control Epilepsy
CA1 CA3 CA1 CA3
Percent
Death
17.91 ± 4.78% 20.57 ± 5.02% 48.86 ± 12.39% a 40.39 ± 11.42%
Percent
Survival
88.15 ± 10.02% 78.89 ± 8.92% 47.32 ± 11.93% a 51.25 ± 14.80%
Notes: In rat hippocampal CA1 and CA3 regions, the number of dead neurones or a
neurones was markedly decreased at 7 days post-SE, as detected by the TUNEL-ass
regions, however, neuronal death or apoptosis was decreased and neuronal surviva
treatment (b P < 0.01, miR-34a antagomir vs antagomir-control, n = 6 /group). The sur
cells × 100%, whereas the neuronal death or apoptotic rate is determined by the numTLE patients [8]. In their study, autopsy control
patients and two mTLE patient groups were compared,
and segregated miRNA signatures for three different pa-
tient groups were revealed. Analysis of the changes of
individual miRNAs identified 165 miRNAs with up- or
down-regulated expression, and 51 of these miRNAs
exhibited a fold change >2.0. Interestingly, the signifi-
cantly deregulated inflammation-associated miR-146a
detected in a TLE patient by Aronica et al. [9] and in the
rat model of TLE by Song et al. [17] and our research
was not identified in Kan’ work. This could be due to
different standards for the selection of TLE patients or
varied criteria for the surgery selection of TLE patients.
In addition, different standards to screen for significantly
deregulated miRNAs may also contribute to a difference
in results. Because the human species exhibits a much
larger pool of miRNAs than rats, it is natural that7 days post-SE in the rat hippocampus
Antagomir Antagomir-control
CA1 CA3 CA1 CA3
a 30.49 ± 8.91% b 24.80 ± 5.80% b 49.35 ± 12.74% 40.69 ± 10.97%
a 72.81 ± 10.60% b 68.28 ± 11.54% b 46.26 ± 9.50% 52.05 ± 14.70%
poptotic cells was significantly increased and the number of surviving
ay and Nissl-staining (a P < 0.01, epilepsy vs control, n = 6 /group). In the same
l was increased significantly after miR-34a antagomir or antagomir-control
vival rate is determined by the number of surviving neurones/ number of total
mber of dead neurones or apoptotic cells/ number of total cells × 100%.
Figure 8 Neurone cell death or apoptosis visualised by the TUNEL-assay in the post-SE rat hippocampus. Overview: A-D; CA1 region:
E-H; CA3 region: I-L. Scale bars: 300 μm (A-D); 30 μm (E-L).
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http://www.biomedcentral.com/1471-2202/13/115miRNA profiling in human TLE patients may result in a
larger number of differentially expressed miRNAs than in
rats with TLE. Some deregulated miRNAs were identified
both in the TLE patients of Kan’s work and in our rat TLEFigure 9 Neurone survival visualised by Nissl-staining in the post-SE
Scale bars: 300 μm (A-D); 30 μm (E-L).model, such as miR-27a, miR-190, miR-203 and miR-
301a. Moreover, Kan’s findings suggest that miRNA
changes in mTLE affect the expression of immunomodu-
latory proteins and further facilitate immune responses.rat hippocampus. Overview: A-D; CA1 region: E-H; CA3 region: I-L.
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http://www.biomedcentral.com/1471-2202/13/115Accordingly, the KEGG pathway analysis of differentially
expressed miRNAs in our research also identified that
pathways in signal transduction and immune system were
significantly enriched. They are consistent with opinion
that immune cells and their inflammatory mediators play
an important role in the pathophysiology of seizures and
epilepsy [18].
Studies by the Henshall group [10,11] identified the
functions of several miRNAs in epilepsy by using mouse
models. In a recent paper, Henshall et al. reported that
miR-134, a miRNA implicated in the control of dendritic
spine morphology, was up-regulated in a mouse model of
status epilepticus, and silencing of miR-134 expression
reduced neurone dendrite spine density and rendered
mice refractory to seizures [10]. The Henshall group also
reported that the expression level of another miRNA,
miR-132, was increased following status epilepticus. Tar-
geting miR-132 in vivo depleted miR-132 levels in the
mouse hippocampus and reduced the seizure-induced
neuronal death [11]. Furthermore, Sano et al. reported
miR-34a up-regulation during seizure-induced neuronal
death in a mouse model [7] and concluded that miR-34a
up-regulation in subfield-specific, temporally restricted
manner is most likely not important for seizure-induced
neuronal death. The strategy of these studies commonly
includes the selection of a target miRNA followed by ex-
pression analysis and the use of an antagomir. The target
miRNAs chosen were mainly brain-specific and possess
functions in either dendritic spine morphogenesis or neur-
onal cell death, as these aspects are important factors for
the development of epilepsy. The immune response and
astrocytes have also been identified to play a role in epilep-
togenesis, yet miRNA functional studies concerning this
aspect of the mechanism of epilepsy are few and more
studies are needed.
The Sano study did not detect a protective effect of the
miR-34a antagomir in the kainic acid-induced status epi-
lepticus mouse model, although they showed an up-
regulation of miR-34a in hippocampal subfields after
status epilepticus. This is somewhat different from our
results, as we have not only found an up-regulation of
miR-34a in the post-status epilepticus rat hippocampus
but also detected a neuro-protective effect of targeting
miR-34a during seizure-induced neuronal death. The rea-
sons for the difference in these results are multi-faceted,
but the most important reason is likely due to the different
epilepsy models used. There are various animal models
with chronic brain dysfunction that are thought to reflect
processes underlying human epilepsy. These chronic mod-
els of epilepsy include the kindling model of TLE and
post-status epilepticus models of TLE. Pilocarpine and kai-
nate models replicate features of human TLE and can be
used as animal preparations for understanding the basic
mechanisms of epileptogenesis [13]. However, differencesbetween the models, species and strains do exist in that
the processes underlying epileptogenesis and the extent of
neuronal damage differs [19]. Furthermore, the degree to
which miR-34a can induce apoptosis may vary between
different models. For example, there is evidence for
miR-34a having varying effects in the promotion of apop-
tosis [20,21]. As up-regulation of miR-34a caused by pro-
longed seizures in vivo has already been shown, we
propose that miR-34a may have a more important role in
the lithium- pilocarpine-induced status epilepticus in rats.
In this model, neuronal injury leads to miR-34a up-regula-
tion, and the protective effect of the miR-34a antagomir in
our study may be related to the ability of miR-34a to in-
duce apoptosis in post-status epilepticus rats. Because
seizure-induced neuronal death may be more prominent
when miR-34a has much stronger pro-apoptotic function,
targeting miR-34a may result in subsequent neuroprotec-
tive effects.
The potential mechanism of miR-34a regulation of
downstream targets needs further mention. miR-34a up-
regulation in a transgenic mice model of Alzheimer’s dis-
ease resulted in a higher expression level of activated
caspase-3 protein by inhibiting bcl-2 translation, suggest-
ing that bcl-2 is an important target for miR-34a [22]. This
is consistent with results from previous studies that identi-
fied bcl-2 as a miR-34a target [23-26]. Because abnormal
expression of miR-34a may contribute to the pathogenesis
of Alzheimer’s disease, it is speculated that seizure-
induced up-regulation of miR-34a may also play a role in
the pathophysiology of epilepsy, at least in part by affect-
ing bcl-2 expression. Prolonged experimental seizures can
cause apoptosis and activate caspases and bcl-2 family
proteins [27]. These apoptosis-associated genes may con-
tribute to mechanisms underlying the development and
maintenance of epilepsy, and modulating these genes can
alter hippocampal damage after seizures. miR-34a as an
epigenetic factor may play a role in modulating apoptosis-
related genes such as bcl-2 and the caspases after status
epilepticus. We focused on the effects of antagonising
miR-34a on the expression of the end-phase apoptosis ex-
ecutor, the caspase-3 gene, to show that pro-apoptotic
miR-34a and caspase-3 expression levels are related.
Seizure-induced neuronal death was less prominent after
treatment with the miR-34a antagomir in the post-status
epilepticus rat hippocampus. What accounts for the neu-
roprotective effect is most likely due to a milder inhibitory
effect of reduced miR-34a expression on bcl-2 translation,
resulting in a lowered expression level of activated
caspase-3 protein and subsequent reduction in seizure-
induced neuronal death.
Conclusions
In conclusion, our results demonstrate the expression
profile of miRNAs in the hippocampus in a rat model of
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http://www.biomedcentral.com/1471-2202/13/115TLE and the pattern of expression increase of the pro-
apoptotic miR-34a in post-SE rats. This study also
demonstrated up-regulation of miR-34a in seizure-
induced neuronal death or apoptosis and showed the
neuro-protective effect of targeting miR-34a. The latter
may be related to a lowered expression level of the acti-
vated caspase-3 protein. The present research provides
insight into the involvement of miRNAs in the mechan-
ism of epilepsy.
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